Agusti-Mejias A, Sánchez CJL, Messeguer BF, Alegre MV

Language: Spanish
References: 14
Page: 197-201
PDF size: 1386.06 Kb.

ABSTRACT

Eczema of the hands (EOH) is the most prevalent hand dermatosis and represents an important healthcare, social and personal, and occupational concern for affected individuals. There exist numerous therapies for EOH although with a very limited efficacy. The first line drugs for EOH are moderate to high potency topical corticosteroids. A considerable percentage of these patients do not respond to topical corticosteroid therapy, or just partially. Oral Alitretinoin has been shown to be effective and safe for the treatment of chronic hand eczema refractory to potent topical corticosteroids, and it has been specifically approved for this use. In this article we describe the case of a female patient diagnosed with severe EOH grave, resistant to all previous therapies (topical and systemic) and who was successfully treated with oral Alitretinoin at 30 mg/day, with very good tolerance to the drug.

REFERENCES

1. Fowler JF, Duh MS, Chng J, Person J, Thorn D, Raut M. A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis 2006; 77: 385-92.

2. Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P. Management of chronic hand eczema. Contact Dermatitis 2007; 57: 203-10.

3. English J, Aldridge R, Gawkrodger DJ, Kownacki S, Statham B, White JM, Williams J. Consensus statement on the management of chronic hand eczema. Clinical and Experimental Dermatology 34: 761-9.

4. Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of he literature. Br J Dermatol 2003; 149: 452-6.

5. NICE: National Institute for Health and Clinical Excellence: full guidance on adalimumab for the treatment of psoriasis TA146. 2008.

6. Blank PR, Blank AA, Szucs TD. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema- a long-term analysis from a Swiss perspective. BMC Dermatology 2010; 10-4.

7. Van Coevorden AM, van Sonderen E, Bouma J, Coenraads PJ. Assessment of severity of hand eczema: discrepancies between patient- and physician-rated scores. Br J Dermatol 2006 ;155: 1217-22.

8. Zapata-González F, Rueda F, Petriz J, Domingo P, Villarroya F, De Madariaga A, Domingo JC. 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J Immunol 2007; 178: 6130-9.

9. Jungersted JM. Changes in skin barrier during tratment with systemic alitretinoin: focus on skin susceptibility and stratum corneumceramides. Arch Dermatol Res 2010; 302: 653-6.

10. Ruzicka T, Larsen FG, Galewicz D, Horváth A, Coenraads PJ, Thestrup-Pedersen K. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140: 1453-9.

11. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008;158: 808-17.

12. Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology 1999; 199: 308-12.

13. Bissonnette R, Worm M, Gerlach B, Guenther L, Cambazard F, Ruzicka T, Maares J, Brown TC. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. The British Journal of Dermatology 2009; 162: 420-6.

14. Blank PR, Blank AA, SzucsTD. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema—a long-term analysis from a Swiss perspective. BMC Dermatol 2010; 10: 4.